Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United St
Prediction: This Stock Could Double By 2031
07:30pm, Friday, 15'th May 2026
Exelixis's main product should continue driving growth through the end of the decade. The company is close to earning approval for a medicine that will take up the mantle thereafter.
Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?
10:51am, Friday, 15'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:01pm, Tuesday, 12'th May 2026
Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
04:05pm, Thursday, 07'th May 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities
EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
01:01pm, Wednesday, 06'th May 2026
EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:41am, Wednesday, 06'th May 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript
03:31am, Wednesday, 06'th May 2026
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
06:30pm, Tuesday, 05'th May 2026
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street
Exelixis (EXEL) Tops Q1 Earnings Estimates
06:16pm, Tuesday, 05'th May 2026
Exelixis (EXEL) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.62 per share a year ago.
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 05'th May 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2026, provided an update on progress toward achieving key corporate objectives
Here's Why Exelixis (EXEL) is a Strong Growth Stock
10:46am, Monday, 04'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:08am, Tuesday, 28'th Apr 2026
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
04:05pm, Tuesday, 21'st Apr 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:42am, Monday, 20'th Apr 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
